What is Haemonetics's R&D?

Haemonetics (HAE) reported R&D of $14.45M in Q1 2026.

How has Haemonetics's R&D changed year-over-year?

Haemonetics's R&D decreased by 21.1% year-over-year, from $18.31M to $14.45M.

What is the long-term trend for Haemonetics's R&D?

Over 4 years (2022 to 2026), Haemonetics's R&D has grown at a 6.3% compound annual growth rate (CAGR), from $46.8M to $59.77M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Haemonetics HAE R&D

R&D at other companies

AbbottABT

$767M+7.1%

TFX

TeleflexTFX

$44.39M+75.5%

MedtronicMDT

$671M-1.9%

LivaNovaLIVN

$58.7M+55.0%

ICU MedicalICUI

$21.28M-8.6%

Merit Medical SystemsMMSI

$22.61M+0.6%

Segments

By segment

See full

Hospital$8.46M-6.2%

Plasma$4.94M+15.4%

Blood Center$1.03M-26.3%

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's R&D?: Haemonetics (HAE) reported R&D of $14.45M in Q1 2026.
How has Haemonetics's R&D changed year-over-year?: Haemonetics's R&D decreased by 21.1% year-over-year, from $18.31M to $14.45M.
What is the long-term trend for Haemonetics's R&D?: Over 4 years (2022 to 2026), Haemonetics's R&D has grown at a 6.3% compound annual growth rate (CAGR), from $46.8M to $59.77M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.